7W5R

KRAS G12V and peptide complex

Summary for 7W5R

• Entry DOI: 10.2210/pdb7w5r/pdb
• Descriptor: Isoform 2B of GTPase KRas, LEU-TYR-ASP-VAL-ALA, MAGNESIUM ION, ... (4 entities in total)
• Functional Keywords: kras, hrev107, structural protein
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 8
• Total formula weight: 124045.56

Authors

Kim, H.J.,Han, C.W.,Jang, S.B. (deposition date: 2021-11-30, release date: 2022-12-07, Last modification date: 2023-11-29)

Primary citation

Kim, H.J.,Han, C.W.,Jeong, M.S.,Jang, S.B.
Structural basis of the oncogenic KRAS mutant and GJ101 complex.
Biochem.Biophys.Res.Commun., 641:27-33, 2023

PubMed Abstract: KRAS mutations occur in a quarter of all human cancers. When activated in its GTP-bound form, RAS stimulates diverse cellular systems, such as cell division, differentiation, growth, and apoptosis through the activations of various signaling pathways, which include mitogen-activated protein kinase (MAPK), phosphoinositide 3 kinases (PI3K), and RAL-GEFs pathways. We found that GJ101 (LYDVA) binds directly to the KRAS mutant (G12V) and showed tumor-suppressive activity. In addition, the GJ101 peptide inhibited KRAS mutant as determined by a [α-P] guanosine triphosphate (GTP) binding assay and suppressed pancreatic cell line in a cell proliferation assay. Herein, the complex structure of KRAS and GJ101 was clarified by X-ray crystallography. Isothermal titration calorimetry showed that GJ101 binds highly with KRAS mutant and the complex structure of KRAS G12VGJ101 complex presented that the residue of Q61 directly interacted with L65 of GJ101. Overall, the results suggest GJ101 be considered a developmental starting point for KRAS G12V inhibitor.

PubMed: 36516586
DOI: 10.1016/j.bbrc.2022.12.019

Experimental method

X-RAY DIFFRACTION (3.87 Å)